The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]
P Barter, J Best, P Colman, M d'Emden, T Davis, P Drury, C Ehnholm, P Glasziou, D Hunt, A Keech, YA Kesaniemi, M Laakso, R Scott, RJ Simes, D Sullivan, M-R Taskinen, M Whiting, J-C Ansquer, B Fraitag, N Anderson Show all
Cardiovascular Diabetology | BMC | Published : 2004
This study is supported by a grant from Laboratoires Fournier SA, Dijon, France and is being coordinated independently by the National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia, and overseen by the study Management Committee.The study is also supported by the National Health and Medical Research Council (NHMRC), Australia (Unit grant, Project grant and Fellowships to A. Keech and J. Simes), without which it would not be possible. We thank the National Heart Foundation, Australia, Diabetes Australia, Diabetes New Zealand, and the Finnish Diabetes Association for endorsing the study. Investigators express their thanks to Rhana Pike and Christelle Foucher for their assistance with the preparation of this manuscript, and the staff of Kadima, Sydney, for efficient management and distribution of study materials. Finally, the many patients participating in the FIELD study are thanked for their untiring contributions.